DOI:
10.1055/s-00034915
Onkologische Welt
LinksClose Window
References
Sternberg CN. et al
Updated overall survival results from PROSPER: A phase 3, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer..
ASCO 2020 Abstract 5515
Access:
We do not assume any responsibility for the contents of the web pages of other providers.